相关实验视频

Updated: Jul 23, 2025

A Matrigel-Based Tube Formation Assay to Assess the Vasculogenic Activity of Tumor Cells

A Matrigel-Based Tube Formation Assay to Assess the Vasculogenic Activity of Tumor Cells

Published on: September 7, 2011

在SCLC中的血统可塑性产生了为血管原生模仿原料的非神经内分泌细胞

Sarah M Pearsall¹, Stuart C Williamson¹, Sam Humphrey¹

¹Cancer Research UK Cancer Biomarker Centre, University of Manchester, United Kingdom; Cancer Research UK Manchester Institute, University of Manchester, United Kingdom; Cancer Research UK Lung Cancer Centre of Excellence, Manchester, United Kingdom.

Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer

|July 16, 2023

概括

在小细胞肺癌 (SCLC) 中,血管仿真 (VM) 是由NOTCH活性非神经内分泌细胞驱动的. 向神经内分泌和非神经内分泌细胞可以改善SCLC患者的治疗结果.

科学领域:

在瘤学瘤学.
癌症生物学癌症生物学
瘤微环境瘤微环境

背景情况:

血管仿真 (VM) 是一种瘤机制,与小细胞肺癌 (SCLC) 的预后不佳有关.
在SCLC中,NOTCH和MYC信号驱动从神经内分泌 (NE) 转向非NE表型,这对转移至关重要.
了解VM有能力的细胞和机制对于SCLC治疗策略至关重要.

研究的目的:

为了定义SCLC中血管性模仿能力较强的细胞的表型.
阐明SCLC中VM背后的分子机制.
研究NE和非NE细胞合作在SCLC进展中的作用.

主要方法:

使用多重免疫组织化学分析VM血管输液和与NE/非NE表型的关联.
在循环瘤细胞衍生型 (CDX) 模型,基因工程小鼠模型 (GEMMs) 和患者活检中评估3D结构和原-整合素相互作用.
使用Matrigel进行体外研究,以评估VM-primed细胞的细胞外基质重塑.

主要成果:

在CDX模型 (23/25),GEMM (2/2) 和SCLC患者活检 (20/20) 中,VM血管被确定为很高的百分比.
发现NOTCH活性非NE细胞具有VM能力,表现出与伪阴极症,血管发育和ECM组织相关的特征.
用VM启动的非NE细胞通过依赖整合素β1的途径将细胞外基质重塑为空洞管道.

结论:

VM代表了SCLC中的功能异质性和可塑性.
识别对VM有能力的细胞和机制有助于对SCLC进展的理解.
建议联合向NE和非NE细胞的治疗策略,以改善SCLC患者的治疗结果.

关键词:

内异质性内异质性神经内分泌瘤是一个神经内分泌瘤.在SCLC中,SCLC是最重要的.瘤的可塑性瘤的可塑性血管生成的模仿.

更多相关视频

Multidimensional Coculture System to Model Lung Squamous Carcinoma Progression

Multidimensional Coculture System to Model Lung Squamous Carcinoma Progression

Published on: March 17, 2020

Flow Cytometry-based Drug Screening System for the Identification of Small Molecules That Promote Cellular Differentiation of Glioblastoma Stem Cells

Flow Cytometry-based Drug Screening System for the Identification of Small Molecules That Promote Cellular Differentiation of Glioblastoma Stem Cells

Published on: January 10, 2018

相关概念视频

Cancer Stem Cells and Tumor Maintenance

Cancer Stem Cells and Tumor Maintenance

Early diagnosis and treatment can often cure cancer. However, even with treatment, residual cells called cancer stem cells (CSC) might remain, often causing tumor recurrence. These cancer stem cells possess the potential for self-renewal and multi-lineage differentiation and are often responsible for the therapeutic resistance displayed in most cancers.
Cancer stem cells are thought to originate from tissue-specific normal stem cells or progenitor cells. The normal stem cells usually reside in...

Adaptive Mechanisms in Cancer Cells

Adaptive Mechanisms in Cancer Cells

Cancer cells accumulate genetic changes at an abnormally rapid rate due to the defects in the DNA repair mechanisms. From an evolutionary perspective, such genetic instability is advantageous for cancer development. Mutant cell lines accumulate a series of beneficial mutations that contribute to their progression into cancer.
Some of the advantages that cancer cells have on normal cells include - enhanced ability to divide without terminally differentiating, induce new blood vessel formation,...

Cancers Originate from Somatic Mutations in a Single Cell

Cancers Originate from Somatic Mutations in a Single Cell

Cancer arises from mutations in the critical genes that allow healthy cells to escape cell cycle regulation and acquire the ability to proliferate indefinitely. Though originating from a single mutation event in one of the originator cells, cancer progresses when the mutant cell lines continue to gain more and more mutations, and finally, become malignant. For example, chronic myelogenous leukemia (CML) develops initially as a non-lethal increase in white blood cells, which progressively...